Skip to main content

Table 1 Patients and disease characteristics

From: GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Main characteristics (N = 15)

N° (%)

Age, years

 Median (range)

52 (42–68)

Sex

 Male

9 (60)

 Female

6 (40)

ECOG performance status

 0

12 (80)

 1

3 (20)

Histological grade

 High

5 (33)

 Low

10 (67)

Time from CRS + HIPEC to relapse

 Median (range, months)

13 (5–36)

 ≤12 months

7 (47)

 >12 months

8 (53)

PCI at the time of CRS + HIPEC

 Median (range)

27 (8–39)

Completeness of cytoreduction

 CC-0

8 (53)

 CC-1

7 (47)

  1. CRS cytoreductive surgery; HIPEC hyperthermic intraperitoneal chemotherapy; PCI peritoneal carcinomatosis index; CC completeness of cytoreduction score